Dear Friends and Supporters,

It is an honor to present our annual report with all of our 2014 successes, including some highlights of the important work being accomplished by the cancer research scientists funded by Concern.

Since our inception in 1968, there have been so many advancements in research and we’ve learned many things about cancer. Perhaps the most important discovery so far is that cancer is not a single disease, but rather hundreds of diseases, each one developing through various pathways with differing responses to available treatments.

So while today millions of cancer patients are winning the battle with this disease, far too many others are not so fortunate; this is why we will continue our quest to conquer cancer for as long as necessary. Our board’s leadership remains steadfastly committed to Concern Foundation’s original “concern”—to provide funding to further the careers of gifted young cancer researchers and put an end to all cancers in our lifetime.

We all know that there is still a long road ahead of us in unlocking the secrets of cancer, so we must continue to develop new avenues for reaching deeper into our community to raise all of the necessary funds to accomplish our mission. We believe strongly that with your support and the precision with which our Scientific Review Committee evaluates each grant proposal, we remain on the right path.

I hope that you continue to be inspired and committed to Concern Foundation after viewing our annual report. Concern funded researchers have been incredibly productive, and we are proud to play a small role in their successes. The independent audited financial report will give you some insight into how efficient we are in putting your donations to the microscope without wasteful spending on overhead.

As Concern Foundation grows year after year, and with the incredible commitment of funders like you, we are closer than ever to fulfilling our mission to conquer this disease once and for all.

Sincerely,

Nancy Eisenstadt

MESSAGE FROM THE PRESIDENT

Nancy Eisenstadt
Board Chair
WHAT

Concern Foundation’s mission is to fund innovative research worldwide in the quest to conquer cancer. Since its founding in 1968, Concern has been a pioneer in the advancement of cancer immunology—the study of the relationship between the immune system and cancer. Our objective is to further the careers of gifted young cancer researchers (Assistant Professor or equivalent) whose work shows great promise, but may not be sufficiently advanced enough in their careers to justify funding from the government or other major funding sources. We focus on finding the most talented scientists with brilliant approaches to unlocking the mystery of cancer.

WHY

“We have reached the point of diminishing returns with the available cancer therapies...it’s no longer acceptable in the 21st century to deliver more chemotherapy or radiation. New, novel therapies are necessary.”

Laurence Cooper, Scientific Review Committee member, perhaps said it best when he stated the importance of providing start up grants to young investigators. Concern Foundation helps to bridge a critical gap in much-needed research funding, and we believe that this unique approach will continue to fuel progress and effective therapies in the treatment of cancer. For 46 years, Concern Foundation has made it possible to transform new ideas from the mind of a researcher into groundbreaking innovations in cancer research.

HOW

New grant proposals are accepted every two years and undergo a rigorous peer review process. Potential applicants are pre-screened with a Letter of Intent, which ensures that only qualified investigators complete the thorough and detailed grant application. Each application is then administratively reviewed. A primary and secondary review follows by Concern Foundation’s Scientific Review Committee. Those applications that advance through these stringent levels are then discussed in further detail at the biennial Scientific Review Committee meeting.

Concern Foundation strives to recruit a cross-section of new and established cancer researchers who comprise our renowned Scientific Review Committee. These exceptional men and women guide our grant review process and help us select the top researchers from a competitive pool of applicants.

Each grant recipient is awarded a $60,000 grant. Provided that sufficient progress is achieved in the first year, Concern awards a second year grant of $60,000. It is the Foundation’s hope that after two years of funding, Concern-sponsored researchers go on to publish their findings in major journals, obtain larger awards to further their work, and advance their positions at respected institutions across the United States and abroad.
**Eyal Arbely**  
Ben-Gurion University of the Negev  
Live cell and structural studies of p53 acetylation induced apoptosis

**Barbara Bedogni**  
Case Western Reserve University  
Targeting a novel MT1-MMP/Notch1 interaction in melanoma

**Michael Berger**  
Hebrew University of Jerusalem - Hadassah School of Medicine  
The role of the quiescence inducer, SLFN2, and its human paralogs in T-ALL

**Michael Boyce**  
Duke University Medical Center  
Protein glycosylation in cancer cell signaling and metabolism

**Mark Chiang**  
The Regents of the University of Michigan  
The collaboration between NOTCH1 and ZMIZ1 in T-cell leukemia

**Muller Fabbri**  
Children’s Hospital, Los Angeles  
Tumor Associated Macrophages exosomic miRNAs in Neuroblastoma biology

**Sarah-Maria Fendt**  
Vlaams Instituut voor Biotechnologie, Belgium  
Regulation of amino acid metabolism and proliferation by S6K1 in cancer

**Ziv Granot**  
Hebrew University of Jerusalem  
Dissecting the mechanisms of tumor-cell recognition by neutrophils

**Deborah Kelly**  
Virginia Polytechnic Institute and State University  
Molecular Basis for BRCA1 in Transcription-Coupled Repair Mechanisms

**Albert Kim**  
Washington University in St. Louis  
Regulation of Brain Cancer Stem Cells by the Anaphase-Promoting Complex

**George-Lucian Moldovan**  
The Pennsylvania State University College of Medicine  
Preservation of genetic stability during DNA replication

**Paolo Provenzano**  
Regents of the University of Minnesota-Twin Cities  
Stroma targeting therapy for pancreatic cancer

**Damien Reynaud**  
Cincinnati Children’s Hospital Medical Center  
Systemic Metabolic Disorders and Leukemic Clonal Dominance

**Jean-Francois Rual**  
The Regents of the University of Michigan  
Aberrant epigenetic control of notch signals in medulloblastoma

**Hae-Ri Song**  
New York University  
Investigating the role of NFIA-NFkB axis in glioma pathogenesis

**Gang ‘Greg’ Wang**  
The University of North Carolina at Chapel Hill  
The role of KDM5 histone lysine demethylases in leukemia and lymphoma

**Elizabeth Yeh**  
Medical University of Southern Carolina  
A Novel Targeted Approach for Triple-negative Breast Cancer 2014
Pediatric Cancer – Brain Tumor
Anat Epstein
Children’s Hospital Los Angeles
Funding matched by Mrs. Mimi Feldman

The Adolescent And Young Adult Program (AYA@USC)
Tissue Registry, Social Worker & Data Coordinator
USC Norris Comprehensive Cancer Center & Children’s Hospital Los Angeles
Co-funded by Marion Brucker Legacy Fund

Population Sciences – Secondary Cancer Development
Smita Bhatia, M.D.
City of Hope
Funding matched by the Teller & Shapiro Family

Hematologic Supportive Care For Children With Cancer:
“Transfusional Iron, Anthracyclines and Cardiac Outcomes among Childhood Cancer Survivors”
Kathy Ruccione
Children’s Hospital Los Angeles

Concern Foundation Stem Cell Research Award
Dr. Arnold Chin and Dr. Andrew Goldstein
UCLA Broad Stem Cell Research Center
Co-funded by Wendy & Tom Nogradi

Understanding The Relationship Between Low Testosterone And Prostate Cancer Risk
Dr. Jeremy Jones
City of Hope
Co-funded by Merryl & David Alpert, Jessica & Eric Nicastro and Julie and Derek Alpert
Elizabeth Yeh, PhD
Medical University of South Carolina
A NOVEL TARGETED APPROACH TO BREAST CANCER

Dr. Elizabeth Yeh, Assistant Professor of Cell and Molecular Pharmacology and Experimental Therapeutics at Medical University of South Carolina, has characterized a novel protein kinase, called Hormonally Up-regulated Neu-associated Kinase (HUNK), which she has determined to be critical in the etiology and progression of human breast cancer.

Triple-negative breast cancer (TNBC) is defined by the absence of specific clinical markers called estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Beyond chemotherapy there are no drugs that are given to TNBC patients on a routine basis. This is a major concern because this type of breast cancer is typically more aggressive thus, finding an effective treatment is crucial.

Dr. Yeh has collected evidence to suggest that HUNK is an appropriate candidate for drug targeting in TNBC. A method to impair HUNK in a mouse model of TNBC was tested and at least in this model, HUNK targeting was found to be effective. Her lab seeks to fully understand what HUNK is doing in TNBC cells in order to effectively target this protein.

In 2014, more than 230,000 women in the United States were diagnosed with breast cancer, making it the second most common cancer among women. Although incidences have increased, death rates from cancer have dropped 34% since 1990, largely because of scientists like Dr. Yeh, who help discover and advance life-saving treatments.

Dr. Yeh’s research project is co-funded by Concern Foundation and the Save the Ta-tas Foundation.

Damien Reynaud, Ph.D.
Cincinnati Children’s Hospital
SYSTEMIC METABOLIC DISORDERS AND LEUKEMIC CLONAL DOMINANCE

During a lab visit to the Cincinnati Children’s Hospital Medical Center, Dr. Damien Reynaud shared the progress of his research that focuses on a link between obesity as a significant risk factor for blood cancers.

Obese individuals have a much higher risk of spontaneously developing leukemia and they are also more difficult to treat, yet little is known about the molecular mechanisms linking obesity and leukemia. We do know the impacts of obesity include added stress on the whole body, which can cause drastic effects like accelerated aging of cells. Since stem cells don’t regenerate, exposure to the stresses of an obese environment forces them to work much harder to adapt and maintain themselves.

Dr. Reynaud specifically looks at the stem cells that are responsible for the life-long production of blood cells. He has found that as these stem cells compensate for their obese surroundings, leading to premature aging, which in turn accelerates the potential for initiation and development of blood cancer.

Since Dr. Reynaud has validated this obesity/leukemia link, he will dedicate the remainder of his Concern Foundation grant exploring and understanding the mechanisms that affect this system. His hope is that once the mechanism for obesity affecting the blood stem cells is determined, they can then move towards controlling its effects.

Dr. Reynaud’s Testimony:
“\text{I would like to express my sincere gratitude to the Concern Foundation and its donors for their support. Seed funds from the Concern Foundation received in 2014 have been essential in establishing my laboratory and initiating an original research program that focuses on the molecular mechanisms linking obesity and blood cancer. Our findings on this project are extremely promising and an abstract featuring our results has been accepted for presentation at the annual meeting of the American Society of Hematology, a key international event dedicated to the treatment of blood diseases. I am grateful that the support of the Concern Foundation has allowed us to create a firm foundation for this exciting project.}”
Karolinska Institute under the direction of George Klein, M.D.
Stockholm Sweden

Concern Foundation, with matching funds from Cancer Research Institute (CRI), provides an annual endowment to the Karolinska Institute in Stockholm, Sweden. Under the direction of George Klein, MD, this grant supported 17 researchers who are developing novel approaches to cancer researchers in the following four areas:

**AREA A. EPSTEIN-BARR VIRUS (EBV)**
A1: Molecular studies of viral latency and transformation
Elena Kashuba
Suhas Darekar
Muhammad Mushtaq
Liang Wu

A2: EBV-host cell interactions
Daniel Salamon
Tomasz Kallas
Abu Eahsan Rasul

**AREA B. ONCOGENES AND TUMOR SUPPRESSOR GENES**
B1: The role of myc in development
Nikolay Zinin

B2: Discovery and analysis of new suppressor genes
Vladimir Kashuba

**AREA C. TUMOR IMMUNOLOGY**
Noemi Nagy
Harsha Madapura

**AREA D. INHIBITION OF TUMOR CELL GROWTH BY STROMA CELLS**
Emilie Flaberg
Hayrettin Guvên
Tatiana Pavlova
Vladimir Kashuba
Twana Alkasalias
Benedek Bozoky

**EBV** - Presence of EBV specific T cell responses in infected humanized mice (mice that have been reconstituted with human immune system). Total splenocyte populations (T and B cells) of EBV infected humanized mice were plated with or without the cell inhibitor cyclosporine A (CsA). After 4 weeks, individual wells were photographed to record the size of the growing clumps representing EBV transformed cells that survived the specific T cell control. Growth of the EBV transformed cells occurred when the T cells were inhibited by CsA (right side of the picture), while these EBV infected B cells did not grow in the presence of T cells (control). This growth pattern proves the existence of EBV specific T cells in the spleen.

**George & Noemi** - George Klein with Noemi Nagy, senior fellow in Eva Klein’s group.

**Laszlo & Emilie** - George Klein’s and Laszlo Szekely’s group, working on tumor resistance, particularly the inhibitory activity of normal fibroblasts on tumor cells.
The Lautenberg Center at Hebrew University
Jerusalem, Israel

For over forty years, Concern Foundation has been proud to support the fine work of the Lautenberg Center. This annual endowment is supported by a generous grant from the Ahmanson Foundation.

The following page summarizes the incredible work of just two of our funded cancer immunology researchers at the Lautenberg Center.

BELOW ARE THE 14 SCIENTISTS CURRENTLY SUPPORTED BY THE CONCERN FOUNDATION ENDOWMENT:

Rami I. Aqeilan        Ruth Gallily
Michael Baniyash      Ygal Haupt
Yinon Ben Neriah      Shoshana Israel
Shlomo Z. Ben-Sasson  Eli Kedar

Moshe Kotler            Michael Steinitz
Ofer Mandelboim        Eitan Yefenof
David Naor             Eli Pikarsky
Lymphocyte Quiescence in Immunity and Leukemia Development

Dr. Michael Berger

Lymphocyte quiescence is defined as a state of reversible growth arrest in which cells remain responsive to activating stimuli and resistant to apoptosis. The immune system maintains a vast repertoire of lymphocytes waiting to respond to microbial invasion. These quiescent, naïve lymphocytes may be activated by antigen engagement and co-stimulation, triggering their expansion and effector functions. Only recently studies have demonstrated that lymphocytes must be actively maintained by the action of molecules that include transcription factors and cell-cycle and metabolism regulators. Our discovery of a mutant mouse with a defective Slfn2 gene (called ‘elektra’) has enabled us to assign a role for this gene in the maintenance of T lymphocyte quiescence. Following this finding we could show that the mechanism by which Slfn2 maintains quiescence in immune cells is by reducing stress levels by regulating the autophagy process in T cells and monocytes. Moreover, we could show that Slfn2 is critical in the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) and that of down regulating Slfn2 attenuates the development and the progression of this disease.

In the past year we could demonstrate that targeting Slfn2 leads to impaired self-renewal capacity of T-ALL initiating cells. In addition we revealed that downregulation of Slfn2 attenuates T-ALL development and progression is partially mediated by the activation of the p53 tumor suppressor pathway and that Slfn5 is the human Slfn2 homolog. In addition, we could describe the mitochondrial activity as a novel mechanism for maintaining quiescence in T cells.

Involvement of APOBEC3B in Cancer Evolution

Professor Moshe Kotler

Second generation sequencing technologies reveal genomic heterogeneity among cells of breast cancer and many other tumors. This heterogeneity is due to chromosomal aberrations and multiple point mutations, which affect genes and regulatory elements, giving rise to sub-clonal populations. At early stages of tumor development, these cell sub-populations cannot typify morphologically, but aggressive populations may dominate the tumor following selection.

Breast, bowel, head/neck, bladder and cervix tumor cells express high amounts of the deaminase APOBEC3B (A3B), which mutates C>T in the cell genome. These mutations could provide advantages to certain cells, making them more aggressive, invasive and drug resistant, and making the tumors hazardous to the patients, underlining the urgent need to characterize the enzyme toward developing anti-A3B inhibitors, which may delay or even prevent tumor evolution.

We have purified and assessed in vitro A3B expressed in mammalian cells; we characterized the biochemical properties of A3B, and discovered the interaction between A3B and cellular DNA. We have one A3B inhibitor, which helps us in defining the molecular domains responsible for A3B activity. These A3B domains will be used in the future as targets for developing efficient anti-A3B therapies to decrease cancer progression and tumor adaptation.
2014 LA and New York City Marathons
The 2014 LA and New York City Marathons collectively raised over $97,000 for Team Concern. It was the fifth consecutive year Concern was an official charity of the LA Marathon, and the fourth for the NYC Marathon. We’re proud of all our runners and walkers who represented Concern Foundation and ran to raise awareness and funds for cancer research, and cannot wait to continue this success.

Beverly Hills Chamber of Commerce Gala
Concern Foundation won Beverly Hills Chamber of Commerce’s Best of Beverly Hills Golden Palm Award in the “Community Support” category. Concern was honored at their annual gala on October 22 with staff and board members in attendance to accept the award.

NSNBN LLP 2014 Annual Charity Golf Tournament
On November 2, NSBN LLP held its annual Charity Golf Tournament, the proceeds of which benefited Concern Foundation. The event raised more than $15,000 for cancer research.

Cycle With Soul
On September 21, Cycle With Soul, Concern’s first SoulCyle charity ride, raised $14,000! The sold-out event was held at SoulCycle Beverly Hills with over 50 participants who not only rode during the class, but raised funds and awareness for cancer research. Many thanks to Courtney Teller, who spearheaded the event and already has plans to make this an annual fundraiser.
Universal Studios Day for the Kids

October 19, 2014

Concern Foundation’s 26th annual Day for the Kids at Universal Studios Hollywood was a smashing success. It was wonderful to spend time with nearly 300 patients and guests. We have received great feedback about what a fun time the kids had and how great it was for volunteers to hear the families’ incredible stories. Our volunteers really do make the day special for these kids.

Holiday Party at Paramount Pictures

December 14, 2014

One of our favorite days of the year is celebrating the holidays with pediatric cancer patients and their families. At Concern Foundation’s annual Holiday Party at Paramount Pictures, all 600 guests got to see a special movie screening, decorate cookies, get their faces painted, enjoy being pampered, create their own sundaes, and receive lots of presents from Santa Claus. We’re so grateful for the opportunity to spend the day with these incredible young people and are already counting down the days until the next holiday party.
**CONCERN FOUNDATION**
**AND SUBSIDIARY**
**(A NONPROFIT ORGANIZATION)**
**CONSOLIDATING STATEMENT OF FINANCIAL POSITION**
**December 31, 2014**

### ASSETS

<table>
<thead>
<tr>
<th>Assets</th>
<th>Concern Foundation</th>
<th>Concern Holding, LLC</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$ 435,539</td>
<td>$ 3,387</td>
<td>$ 438,926</td>
</tr>
<tr>
<td>Investments</td>
<td>4,020,252</td>
<td>-</td>
<td>4,020,252</td>
</tr>
<tr>
<td>Pledges and other receivables, net</td>
<td>594,771</td>
<td>-</td>
<td>594,771</td>
</tr>
<tr>
<td>Beneficial interest in charitable remainder trusts</td>
<td>254,172</td>
<td>-</td>
<td>254,172</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>11,330</td>
<td>-</td>
<td>11,330</td>
</tr>
<tr>
<td>Other assets</td>
<td>63,662</td>
<td>-</td>
<td>63,662</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$ 5,379,726</strong></td>
<td><strong>$ 3,387</strong></td>
<td><strong>$ 5,383,113</strong></td>
</tr>
</tbody>
</table>

### LIABILITIES AND NET ASSETS

<table>
<thead>
<tr>
<th>Liabilities</th>
<th>Concern Foundation</th>
<th>Concern Holding, LLC</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grants payable</td>
<td>$ 510,000</td>
<td>-</td>
<td>$ 510,000</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>40,026</td>
<td>-</td>
<td>40,026</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>714,771</td>
<td>-</td>
<td>714,771</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>1,264,797</strong></td>
<td>-</td>
<td><strong>1,264,797</strong></td>
</tr>
</tbody>
</table>

### Commitments

### Net assets

| Undesignated                                | 1,346,357          | 3,387                | 1,349,744 |
| Unrestricted                                | 500,000            | -                    | 500,000   |
| **Total unrestricted**                      | **1,846,357**      | **3,387**            | **1,849,744** |
| Temporarily restricted                       | 348,200            | -                    | 348,200   |
| Permanently restricted                       | 1,920,372          | -                    | 1,920,372 |
| **Total net assets**                        | **4,114,929**      | **3,387**            | **4,118,316** |

**Total liabilities and net assets**

| **Total liabilities and net assets**         | **$ 5,379,726**    | **$ 3,387**          | **$ 5,383,113** |
### CONCERN FOUNDATION
AND SUBSIDIARY
(A NONPROFIT ORGANIZATION)
CONSOLIDATING STATEMENT OF ACTIVITIES
For the Year Ended December 31, 2014

<table>
<thead>
<tr>
<th></th>
<th>Concern Foundation</th>
<th>Concern Foundation Holding, LLC</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue and support</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>$ 464,248</td>
<td>$ -</td>
<td>$ 464,248</td>
</tr>
<tr>
<td>Special events, net</td>
<td>1,005,084</td>
<td>-</td>
<td>1,005,084</td>
</tr>
<tr>
<td>Campaign</td>
<td>27,306</td>
<td>-</td>
<td>27,306</td>
</tr>
<tr>
<td>Investment income</td>
<td>104,217</td>
<td></td>
<td>104,217</td>
</tr>
<tr>
<td><strong>Decrease in value of charitable remainder trusts</strong></td>
<td>(5,066)</td>
<td></td>
<td>(5,066)</td>
</tr>
<tr>
<td><strong>Net realized losses on investments</strong></td>
<td>(5,802)</td>
<td>-</td>
<td>(5,802)</td>
</tr>
<tr>
<td><strong>Total revenue and support</strong></td>
<td><strong>1,589,987</strong></td>
<td><strong>-</strong></td>
<td><strong>1,589,987</strong></td>
</tr>
<tr>
<td><strong>Functional expenses</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program services</td>
<td>1,848,340</td>
<td>-</td>
<td>1,848,340</td>
</tr>
<tr>
<td>Management and general</td>
<td>82,154</td>
<td>-</td>
<td>82,154</td>
</tr>
<tr>
<td>Fundraising</td>
<td>223,406</td>
<td>-</td>
<td>223,406</td>
</tr>
<tr>
<td><strong>Total functional expenses</strong></td>
<td><strong>2,153,900</strong></td>
<td><strong>-</strong></td>
<td><strong>2,153,900</strong></td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td>(563,913)</td>
<td>-</td>
<td>(563,913)</td>
</tr>
<tr>
<td><strong>Net assets, beginning of year</strong></td>
<td>4,678,842</td>
<td>3,387</td>
<td>4,682,229</td>
</tr>
<tr>
<td><strong>Net assets, end of year</strong></td>
<td><strong>$ 4,114,929</strong></td>
<td>$ 3,387</td>
<td><strong>$ 4,118,316</strong></td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nancy Eisenstadt</td>
<td>Chair</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Derek Alpert</td>
<td>President</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lexy and John Carroll</td>
<td>Vice Chairpersons</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael Firestein</td>
<td>Secretary/Legal Counsel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marc Lauter</td>
<td>Chief Financial Officer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anne Barnett</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bill Barnett</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harvey Beesen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mark Bolour</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sheila Bolour</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barry Brucker</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sue Brucker</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carla Daly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>David Entin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steve Fortner</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steve Freed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jim Freedman</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alan Gittelson</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nancy Gittelson</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robert Goldman</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lorene Goldman</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jackie Gottlieb</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stanley Gottlieb</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jim Hausberg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Max Liszt</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marc Luber</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ian Metrose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lauri Metrose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frank Mottek</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jessica Nicastro</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wendy Nogradi</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tom Nogradi</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Debbie Powell</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rick Powell</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joyce Powell</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Larry Powell</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laurie Resch</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>June Miller Richards</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dana Schwartz</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lisi Teller</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steve Teller</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steve Ullman</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Briana Vickers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scott Vickers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myrna Zimmerman</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stan Zimmerman</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Concern Foundation has raised over $57 Million to fund cancer research through donations from individuals like yourself! Help us **CONquer can**CER N**ow**.

- Make a monetary donation today.
- Become an Annual Sponsor and enjoy sponsorship benefits
- Send a tribute in honor or in memory of someone special
- Be a part of our signature Block Party fund raising event
- Start your own fundraiser
- Be a part of Team Concern by participating in the LA marathon or another athletic event or activity of your choice
- Take steps to create a planned gift
- Donate your time and expertise by volunteering
- Get your place of business involved and become a community partner or corporate sponsor
- Help spread the word about Concern Foundation

Each year, 14 million men, women, and children worldwide are diagnosed with some type of cancer. Continued research to find better, smarter, more effective treatments is urgently needed. Only with your help can we continue to fund innovative research and bring breakthrough treatments and “cures” to more cancer patients.
CONCERN FOUNDATION
FOR CANCER RESEARCH

11111 West Olympic Blvd. Suite 214
Los Angeles, CA 90064
tel: 310.360.6100
fax: 310.473.8300
info@concernfoundation.org
www.concernfoundation.org

Please consider Concern Foundation in your estate plan.